HMG-CoA Reductase Inhibitor Use in the Aged. A Review of Clinical Experience

Overview

Journal Drugs Aging

Specialties Geriatrics
Pharmacology

Date 1992 Nov 1

PMID 1493355

Citations 3

Authors

C J Lintott

R S Scott

Affiliations

Soon will be listed here.

Abstract

While the benefit of cholesterol-lowering in the elderly has yet to be proven in clinical trials, individuals at high risk of coronary events who otherwise enjoy a good quality of life, should not be denied cholesterol-lowering therapy on the basis of age alone. Moreover, hypolipidaemic drugs are already extensively used in the aged. The HMG-CoA reductase inhibitors lovastatin, simvastatin and pravastatin are potent well tolerated hypolipidaemic therapies in young subjects. Although there have been few studies on their use in elderly subjects, the available data suggest the efficacy and safety of HMG-CoA reductase inhibitors in similar to that established for younger age groups.

Citing Articles

How well tolerated are lipid-lowering drugs?.

Tomlinson B, Chan P, Lan W Drugs Aging. 2001; 18(9):665-83.

PMID: 11599634 DOI: 10.2165/00002512-200118090-00003.

Treatment of non-insulin-dependent diabetes mellitus and its complications. A state of the art review.

Ilarde A, Tuck M Drugs Aging. 1994; 4(6):470-91.

PMID: 8075474 DOI: 10.2165/00002512-199404060-00004.

Efficacy and safety of fluvastatin, a new HMG CoA reductase inhibitor, in elderly hypercholesterolaemic women.

Baggio G, DE CANDIA O, Forte P, Mello F, Andriolli A, Donazzan S Drugs. 1994; 47 Suppl 2:59-63.

PMID: 7517835 DOI: 10.2165/00003495-199400472-00011.

References

Glueck C, Speirs J, Tracy T . Safety and efficacy of combined gemfibrozil-lovastatin therapy for primary dyslipoproteinemias. J Lab Clin Med. 1990; 115(5):603-9. View

Hoogerbrugge N, MOL M, Van Dormaal J, Rustemeijer C, Muls E, Stalenhoef A . The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia. J Intern Med. 1990; 228(3):261-6. DOI: 10.1111/j.1365-2796.1990.tb00229.x. View

Ahmad S . Lovastatin. Warfarin interaction. Arch Intern Med. 1990; 150(11):2407. DOI: 10.1001/archinte.150.11.2407. View

Endo A, Kuroda M, Tsujita Y . ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo). 1976; 29(12):1346-8. DOI: 10.7164/antibiotics.29.1346. View

Koppensteiner R, Minar E, Ehringer H . Effect of lovastatin on hemorheology in type II hyperlipoproteinemia. Atherosclerosis. 1990; 83(1):53-8. DOI: 10.1016/0021-9150(90)90130-b. View

Wiklund O, Angelin B, Fager G, Eriksson M, Olofsson S, Berglund L . Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. J Intern Med. 1990; 228(3):241-7. DOI: 10.1111/j.1365-2796.1990.tb00225.x. View

Tikkanen M, Tilvis R . Hypercholesterolaemia in aged patients. To treat or not to treat?. Drugs Aging. 1991; 1(6):427-30. DOI: 10.2165/00002512-199101060-00002. View

Yuan J, Tsai M, Hegland J, Hunninghake D . Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis. 1991; 87(2-3):147-57. DOI: 10.1016/0021-9150(91)90017-w. View

. HMG-CoA reductase inhibitors for hypercholesterolemia. N Engl J Med. 1988; 319(18):1222-3. DOI: 10.1056/NEJM198811033191811. View

10.

Stein E, Kreisberg R, Miller V, Mantell G, Washington L, Shapiro D . Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I. Arch Intern Med. 1990; 150(2):341-5. View

11.

Germershausen J, HUNT V, Bostedor R, Bailey P, KARKAS J, ALBERTS A . Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Commun. 1989; 158(3):667-75. DOI: 10.1016/0006-291x(89)92773-3. View

12.

. A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV. Am J Cardiol. 1990; 66(8):22B-30B. DOI: 10.1016/0002-9149(90)90437-6. View

13.

Yoshino G, Kazumi T, Iwai M, Matsushita M, MATSUBA K, Uenoyama R . Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514). Atherosclerosis. 1989; 75(1):67-72. DOI: 10.1016/0021-9150(89)90208-6. View

14.

Erkelens D, Baggen M, van Doormaal J, Kettner M, Koningsberger J, MOL M . Clinical experience with simvastatin compared with cholestyramine. Drugs. 1988; 36 Suppl 3:87-92. DOI: 10.2165/00003495-198800363-00018. View

15.

McTavish D, Sorkin E . Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs. 1991; 42(1):65-89. DOI: 10.2165/00003495-199142010-00005. View

16.

French J, White H, Greaves S . Simvastatin therapy for hypercholesterolaemia in patients with coronary heart disease. N Z Med J. 1990; 103(883):41-3. View

17.

OBrien R, Simons L, Clifton P, Cooper M, Jennings G, Jerums G . Comparison of simvastatin and cholestyramine in the treatment of primary hypercholesterolaemia. Med J Aust. 1990; 152(9):480-3. View

18.

Pan H, DeVault A, Wang-Iverson D, Ivashkiv E, Swanson B, SUGERMAN A . Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol. 1990; 30(12):1128-35. DOI: 10.1002/j.1552-4604.1990.tb01856.x. View

19.

HAVEL R, Hunninghake D, Illingworth D, Lees R, Stein E, Tobert J . Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. Ann Intern Med. 1987; 107(5):609-15. DOI: 10.7326/0003-4819-107-5-609. View

20.

Paolisso G, Sgambato S, De Riu S, Gambardella A, Verza M, Varricchio M . Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics. Eur J Clin Pharmacol. 1991; 40(1):27-31. DOI: 10.1007/BF00315135. View